Abstract
Bioreductive drugs, for use as hypoxic cell cytotoxic agents or radiosensitizers selectively active against cells deficient in oxygen, have a promising future to supplement and augment existing anticancer modalities. With improvements in cancer therapy and an increase in the number of patients who survive, there is mounting concern that agents used to treat cancer may themselves have the potential to induce new malignancies.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
T. K. Hei, C. R. Geard, R. S. Osmak, and E. J. Hall, In vitro assessment of the oncogenic potential of nitroiraidazole radiosensitizers, Int. J. Radiat. Oncology Biol. Phy. 11: 1653–1658 (1985).
E. J. Hall and T. K. Hei, Oncogenic transtorramg potential of nitroimidazole radiosensitizers, Int. J. Radiat. Oncology Biol. Phv. 16:1231–1234 (1989).
E. J. Hall and T. K. Hei, The effect of bioreduction on the oncogenicity of nitroimidazoles, Biochem. Pharmacology 34:93–94 (1986).
I. J. Stratford, P. O’Neill, P. W. Sheldon, A. R. J. Silver, J. M. Walling, and G. E. Adams, RSU-1069, a nitroimidazole containing an aziridine group: bioreduction greatly increases cytotoxicity under hypoxic conditions, Biochem. Pharmacology 35:105–110 (1986).
R. C. Miller, R. S. Osmak, M. Zimmerman, and E. J. Hall,, Sensitizers, protectors and oncogenic transformation in vitro. Int. J. Radiat. Oncology Biol. Phy. 8:771–775 (1982).
L. Roizin-Towle, J. P. Pirro, and E. J. Hall, Studies with bifunctional bioreductive drugs: II. Cytotoxicity assayed with A-549 lung carcinoma cells of human origin, In press.
I. Ahmed, T. C. Jenkins, J. M. Walling, I. J. Stratford, P. W. Sheldon, G. E. Adams, and E. M. Fielden, Analogues of RSU-1069: Radiosensitization and toxicities in vitro and in vivo. Int. J. Radiât. Oncology Biol. Phy. 12: 1079–1081 (1986).
J. M. Brown, N. Y. Yu, D. M. Biown, and W. Lee,, SR-2508: A 2- nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use, Int. J. Radiat. Oncology Biol. Phy. 7:695–703 (1981).
P. O’Neill, T. C. Jenkins, I. J. Stratford, A. R. J. Silver, I. Ahmed, S. S. McNeil, E. M. Fielden, and G. E. Adams, Mechanism of action of some bioreducible & nitroimidazoles: comparison of in vitro cytotoxicity and ability to induce DNA strand breakage, Anti-cancer Drug Design 1: 271–280 (1987).
United Nations Scientific Committee on the Effects of Atomic Radiation: Sources and Effects of Ionizing Radiation, New York, United Nations (1986).
C. N. Coleman, L. Noll, A. E. Howes, J. R. Harris, J. Zakar, and R. Kramer, Initial results of a plan I trial of continuous infusion of SR-2508 (etanidazole): A radiation therapy oncology group study, Int. J. Radiat. Oncol. Biol. Phy. 16: 1085–1087 (1989).
C. N. Coleman, R. C. Urtasun, T. H. Wasserman, S. Hancock, J. W. Harris, J. Halsey, and V. K. Hirst, Initial report of the plan I trial of the hypoxic cell radiosensitizer ST-2508, Int. J. Radiat. Oncol. Biol. Phy. 10: 1749–1753 (1984).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer Science+Business Media New York
About this chapter
Cite this chapter
Hall, E.J., Hei, T.K. (1990). The Oncogenic Potential of Bioreductive Drugs. In: Adams, G.E., Breccia, A., Fielden, E.M., Wardman, P. (eds) Selective Activation of Drugs by Redox Processes. NATO ASI Series, vol 198. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3768-7_28
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3768-7_28
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6679-9
Online ISBN: 978-1-4615-3768-7
eBook Packages: Springer Book Archive